Suzhou, China

Zhengli Xie

This inventor holds 2 USPTO granted patents. Top assignee: Azenta US, Inc.. Active years: 2025-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhengli Xie. Retrieved from https://idiyas.com/inventor/zhengli-xie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 50.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Zhengli Xie: Innovator in Biotechnology

Introduction

Zhengli Xie is a prominent inventor based in Suzhou, China. He has made significant contributions to the field of biotechnology, holding a total of 2 patents. His work focuses on innovative solutions that enhance biological processes and applications.

Latest Patents

Zhengli Xie's latest patents include "Promoter and Use Thereof" and "Promoter and Carrier Composed of Same and Application Thereof." These patents reflect his commitment to advancing biotechnological methods and applications.

Career Highlights

Zhengli Xie is currently employed at Azenta US, Inc., where he continues to develop and refine his innovative ideas. His expertise in biotechnology has positioned him as a valuable asset to his company and the industry at large.

Collaborations

Zhengli has collaborated with notable colleagues, including Tianming Qi and Aihua Feng. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Zhengli Xie's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to inspire advancements that benefit various applications in science and technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…